KRAS Testing and Epidermal Growth Factor Receptor Inhibitor Treatment for Colorectal Cancer in Community Settings

BACKGROUND: In metastatic colorectal cancer (mCRC), mutations in the KRAS gene predict poor response to epidermal growth factor receptor (EGFR) inhibitors. Clinical treatment guidelines now recommend KRAS testing if EGFR inhibitors are considered. Our study investigates the clinical uptake and utili...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Webster, Jennifer, Kauffman, Tia L., Feigelson, Heather Spencer, Pawloski, Pamala A., Onitilo, Adedayo A., Potosky, Arnold L., Cross, Deanna, Meier, Paul R., Mirabedi, Anousheh S., Delate, Thomas, Daida, Yihe, Williams, Andrew E., Alexander, Gwen L., McCarty, Catherine A., Honda, Stacey, Kushi, Lawrence H., Goddard, Katrina A.B.
Formato: Artigo
Idioma:Inglês
Publicado: 2012
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3567775/
https://ncbi.nlm.nih.gov/pubmed/23155138
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1055-9965.EPI-12-0545
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares